FHTX · NASDAQ
Foghorn Therapeutics Inc.
$2.05 -0.01 (-0.50%)
Company overview
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company that discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within this system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome, as well as FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. Foghorn is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM, and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $122M
- Employees
- 112
- Headquarters
- Cambridge, MA
- Website
- foghorntx.com
- CEO
- Adrian H. Gottschalk
- Listed
- October 23, 2020
- P/E
- -1.75
- Dividend yield
- 0.00%
Company financials
- Revenue
- $28.2M
- Gross profit
- $6.3M
- Operating income
- -$80.8M
- EBITDA
- -$72.2M
- Net income
- -$75.3M
- EPS
- -$1.17
- Total assets
- $222M
- Total debt
- $42M
- Gross margin
- 22.26%
- Net margin
- -266.88%
- Earnings yield
- -57.07%
FHTX
1D
NASDAQ
O1.99H2.06L1.98C2.04+0.04 (+2.00%)Vol232.36K